- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval December 18, 2020).
- Why 3/10
- Orgovyx is already approved and commercially marketed with no pending FDA decision or pivotal readout. For Pfizer, it is a co-commercialized product shared with Sumitomo Pharma and represents a very small fraction of Pfizer's $63B+ annual revenue. No hard binary catalyst exists in the next 12 months, capping the score at 3-5 per the rubric for approved drugs with no pending regulatory decision.
Orgovyx is an already-approved, commercially mature drug with no upcoming FDA decision or pivotal readout. For Pfizer investors, the drug's sales trajectory matters only at the margins of a $63B+ revenue base. The next notable event is whether Orgovyx crosses the $1 billion annual sales threshold, which would trigger a $325 million milestone payment from Pfizer to Sumitomo (already factored into Sumitomo's guidance). Watch Sumitomo Pharma's quarterly reports for Orgovyx sales trends and any label expansion efforts.
Price Chart
Executive Summary
Orgovyx (relugolix) is an oral GnRH receptor antagonist approved by the FDA in December 2020 for advanced prostate cancer. It was the first oral hormone therapy for this indication, offering a convenient once-daily pill alternative to injectable treatments like Lupron. Originally developed by Myovant Sciences (acquired by Sumitomo Pharma in 2023), Orgovyx is co-commercialized in the US and Canada by Sumitomo Pharma America and Pfizer under a 2020 profit-sharing collaboration. The drug has posted strong sales growth (approaching $1 billion annually) but is a very small component of Pfizer's $63B+ revenue base. No new regulatory catalysts are pending for this already-approved, marketed drug.
How It Works
Orgovyx is a once-daily pill that blocks a hormone signal in the brain (GnRH), which in turn stops the testicles from producing testosterone. Since prostate cancer cells rely on testosterone to grow, lowering testosterone levels slows the cancer's progression. It is the first oral version of this type of therapy, previously only available as injections or implants.
Trial Status
Orgovyx was approved by the FDA on December 18, 2020 based on the Phase 3 HERO trial, which showed it suppressed testosterone faster and with better cardiovascular safety than the injectable standard-of-care leuprolide (Lupron). Post-approval, the OPTYX real-world study (NCT05467176) completed enrollment and reported that over 52% of patients preferred oral Orgovyx over injectable ADT. The drug is commercially marketed in the US and has regulatory approvals in Europe and other regions.
The Two-Sided Case
Upcoming Catalysts
- Potential $1 billion annual sales milestone triggering $325M milestone payment (already expected by Sumitomo management for FY2026)
- Possible label expansion or new indication studies for relugolix (e.g., combination therapy for women's health as Myfembree)
- Patent challenges: one Paragraph IV challenge filed; last Orange Book patent expires September 29, 2037
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report